High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine
Abstract In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with malaria receiving artemisinin combination therapies. Until recently, relevant K13 mutations had been mostly absent from Africa. Between 2018 and...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2022-04, Vol.225 (8), p.1411-1414 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1414 |
|---|---|
| container_issue | 8 |
| container_start_page | 1411 |
| container_title | The Journal of infectious diseases |
| container_volume | 225 |
| creator | Straimer, Judith Gandhi, Preetam Renner, Katalin Csermak Schmitt, Esther K |
| description | Abstract
In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with malaria receiving artemisinin combination therapies. Until recently, relevant K13 mutations had been mostly absent from Africa. Between 2018 and 2019, a phase 2 clinical study with 186 patients was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized and treated with artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance. Notwithstanding, efficacy of artemether-lumefantrine remained high in Rwanda, with a 94.4% polymerase chain reaction–corrected cure rate.
A phase 2 clinical study was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized to artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance. |
| doi_str_mv | 10.1093/infdis/jiab352 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9016418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/infdis/jiab352</oup_id><sourcerecordid>2659008839</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-dfda35d4031ec85055595e3e2fa2881a630f8e063b284e6e629389167c1892f93</originalsourceid><addsrcrecordid>eNqFkU9vEzEQxS0EoqFw5YgscYHDtv6zdrwXpCiCtiKICIo4Ws7uuHG0awfb24pvwsetow0VcOHkkfybN2_mIfSSkjNKGn7uvO1cOt85s-GCPUIzKvi8kpLyx2hGCGMVVU1zgp6ltCOE1FzOn6ITXjMq6zmZoV-X7maL1xFuTQ--BRwsXvcmDaFz44Ct6Vu3N7GUHynHn8Zssgs-YefxlzvjO4OvEl6kFFpnMnT4u8tb_LUPd3htokkuA172UMqD9sJmiPg6gskD-DzBi5hhgLyFWK3GAazxOToPz9GTMjzBi-N7ir59eH-9vKxWny-ulotV1XLFctXZznDR1YRTaJUgQohGAAdmDVOKGsmJVUAk3zBVgwTJGq4aKudtuQuzDT9F7ybd_bgZoGuLr2h6vY9uMPGnDsbpv3-82-qbcKsbUk5IVRF4cxSI4ccIKevBpRb63ngIY9JM1KomVBFR0Nf_oLswRl_W00yKhhCl-MHR2US1MaQUwT6YoUQfQtdT6PoYeml49ecKD_jvlAvwdgLCuP-f2D10Fbpy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2659008839</pqid></control><display><type>article</type><title>High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Straimer, Judith ; Gandhi, Preetam ; Renner, Katalin Csermak ; Schmitt, Esther K</creator><creatorcontrib>Straimer, Judith ; Gandhi, Preetam ; Renner, Katalin Csermak ; Schmitt, Esther K</creatorcontrib><description>Abstract
In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with malaria receiving artemisinin combination therapies. Until recently, relevant K13 mutations had been mostly absent from Africa. Between 2018 and 2019, a phase 2 clinical study with 186 patients was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized and treated with artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance. Notwithstanding, efficacy of artemether-lumefantrine remained high in Rwanda, with a 94.4% polymerase chain reaction–corrected cure rate.
A phase 2 clinical study was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized to artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiab352</identifier><identifier>PMID: 34216470</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Animals ; Antimalarials - pharmacology ; Antimalarials - therapeutic use ; Artemether ; Artemether - therapeutic use ; Artemether, Lumefantrine Drug Combination - therapeutic use ; Artemisinin ; Drug Resistance - genetics ; Erythrocytes ; Gabon ; Gene frequency ; Humans ; Major and Brief Reports ; Malaria ; Malaria, Falciparum - drug therapy ; Malaria, Falciparum - epidemiology ; Malaria, Falciparum - parasitology ; Mutation ; Parasites ; Patients ; Plasmodium falciparum ; Plasmodium falciparum - genetics ; Prevalence ; Protozoan Proteins - genetics ; Rwanda - epidemiology</subject><ispartof>The Journal of infectious diseases, 2022-04, Vol.225 (8), p.1411-1414</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-dfda35d4031ec85055595e3e2fa2881a630f8e063b284e6e629389167c1892f93</citedby><cites>FETCH-LOGICAL-c382t-dfda35d4031ec85055595e3e2fa2881a630f8e063b284e6e629389167c1892f93</cites><orcidid>0000-0002-3818-9887</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34216470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Straimer, Judith</creatorcontrib><creatorcontrib>Gandhi, Preetam</creatorcontrib><creatorcontrib>Renner, Katalin Csermak</creatorcontrib><creatorcontrib>Schmitt, Esther K</creatorcontrib><title>High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Abstract
In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with malaria receiving artemisinin combination therapies. Until recently, relevant K13 mutations had been mostly absent from Africa. Between 2018 and 2019, a phase 2 clinical study with 186 patients was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized and treated with artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance. Notwithstanding, efficacy of artemether-lumefantrine remained high in Rwanda, with a 94.4% polymerase chain reaction–corrected cure rate.
A phase 2 clinical study was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized to artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance.</description><subject>Animals</subject><subject>Antimalarials - pharmacology</subject><subject>Antimalarials - therapeutic use</subject><subject>Artemether</subject><subject>Artemether - therapeutic use</subject><subject>Artemether, Lumefantrine Drug Combination - therapeutic use</subject><subject>Artemisinin</subject><subject>Drug Resistance - genetics</subject><subject>Erythrocytes</subject><subject>Gabon</subject><subject>Gene frequency</subject><subject>Humans</subject><subject>Major and Brief Reports</subject><subject>Malaria</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Malaria, Falciparum - epidemiology</subject><subject>Malaria, Falciparum - parasitology</subject><subject>Mutation</subject><subject>Parasites</subject><subject>Patients</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium falciparum - genetics</subject><subject>Prevalence</subject><subject>Protozoan Proteins - genetics</subject><subject>Rwanda - epidemiology</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqFkU9vEzEQxS0EoqFw5YgscYHDtv6zdrwXpCiCtiKICIo4Ws7uuHG0awfb24pvwsetow0VcOHkkfybN2_mIfSSkjNKGn7uvO1cOt85s-GCPUIzKvi8kpLyx2hGCGMVVU1zgp6ltCOE1FzOn6ITXjMq6zmZoV-X7maL1xFuTQ--BRwsXvcmDaFz44Ct6Vu3N7GUHynHn8Zssgs-YefxlzvjO4OvEl6kFFpnMnT4u8tb_LUPd3htokkuA172UMqD9sJmiPg6gskD-DzBi5hhgLyFWK3GAazxOToPz9GTMjzBi-N7ir59eH-9vKxWny-ulotV1XLFctXZznDR1YRTaJUgQohGAAdmDVOKGsmJVUAk3zBVgwTJGq4aKudtuQuzDT9F7ybd_bgZoGuLr2h6vY9uMPGnDsbpv3-82-qbcKsbUk5IVRF4cxSI4ccIKevBpRb63ngIY9JM1KomVBFR0Nf_oLswRl_W00yKhhCl-MHR2US1MaQUwT6YoUQfQtdT6PoYeml49ecKD_jvlAvwdgLCuP-f2D10Fbpy</recordid><startdate>20220419</startdate><enddate>20220419</enddate><creator>Straimer, Judith</creator><creator>Gandhi, Preetam</creator><creator>Renner, Katalin Csermak</creator><creator>Schmitt, Esther K</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3818-9887</orcidid></search><sort><creationdate>20220419</creationdate><title>High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine</title><author>Straimer, Judith ; Gandhi, Preetam ; Renner, Katalin Csermak ; Schmitt, Esther K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-dfda35d4031ec85055595e3e2fa2881a630f8e063b284e6e629389167c1892f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Antimalarials - pharmacology</topic><topic>Antimalarials - therapeutic use</topic><topic>Artemether</topic><topic>Artemether - therapeutic use</topic><topic>Artemether, Lumefantrine Drug Combination - therapeutic use</topic><topic>Artemisinin</topic><topic>Drug Resistance - genetics</topic><topic>Erythrocytes</topic><topic>Gabon</topic><topic>Gene frequency</topic><topic>Humans</topic><topic>Major and Brief Reports</topic><topic>Malaria</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Malaria, Falciparum - epidemiology</topic><topic>Malaria, Falciparum - parasitology</topic><topic>Mutation</topic><topic>Parasites</topic><topic>Patients</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium falciparum - genetics</topic><topic>Prevalence</topic><topic>Protozoan Proteins - genetics</topic><topic>Rwanda - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Straimer, Judith</creatorcontrib><creatorcontrib>Gandhi, Preetam</creatorcontrib><creatorcontrib>Renner, Katalin Csermak</creatorcontrib><creatorcontrib>Schmitt, Esther K</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Straimer, Judith</au><au>Gandhi, Preetam</au><au>Renner, Katalin Csermak</au><au>Schmitt, Esther K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2022-04-19</date><risdate>2022</risdate><volume>225</volume><issue>8</issue><spage>1411</spage><epage>1414</epage><pages>1411-1414</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Abstract
In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with malaria receiving artemisinin combination therapies. Until recently, relevant K13 mutations had been mostly absent from Africa. Between 2018 and 2019, a phase 2 clinical study with 186 patients was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized and treated with artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance. Notwithstanding, efficacy of artemether-lumefantrine remained high in Rwanda, with a 94.4% polymerase chain reaction–corrected cure rate.
A phase 2 clinical study was conducted in Mali, Gabon, Ghana, Uganda, and Rwanda. Patients with malaria were randomized to artemether-lumefantrine or cipargamin. Here we report an allele frequency of 22% for R561H in Rwanda and associated delayed parasite clearance.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34216470</pmid><doi>10.1093/infdis/jiab352</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-3818-9887</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2022-04, Vol.225 (8), p.1411-1414 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9016418 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Antimalarials - pharmacology Antimalarials - therapeutic use Artemether Artemether - therapeutic use Artemether, Lumefantrine Drug Combination - therapeutic use Artemisinin Drug Resistance - genetics Erythrocytes Gabon Gene frequency Humans Major and Brief Reports Malaria Malaria, Falciparum - drug therapy Malaria, Falciparum - epidemiology Malaria, Falciparum - parasitology Mutation Parasites Patients Plasmodium falciparum Plasmodium falciparum - genetics Prevalence Protozoan Proteins - genetics Rwanda - epidemiology |
| title | High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A55%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20Prevalence%20of%20Plasmodium%20falciparum%20K13%20Mutations%20in%20Rwanda%20Is%20Associated%20With%20Slow%20Parasite%20Clearance%20After%20Treatment%20With%20Artemether-Lumefantrine&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Straimer,%20Judith&rft.date=2022-04-19&rft.volume=225&rft.issue=8&rft.spage=1411&rft.epage=1414&rft.pages=1411-1414&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiab352&rft_dat=%3Cproquest_pubme%3E2659008839%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2659008839&rft_id=info:pmid/34216470&rft_oup_id=10.1093/infdis/jiab352&rfr_iscdi=true |